Merck & CompanyvsNeurocrine Biosciences

MRK and NBIX stock compared: price, dividend, valuation and results, from SEC filings.

MRK

Merck & Company, Inc.

$144.46

Value $357B

-2.23%
MRK's page

NBIX

Neurocrine Biosciences, Inc.

$165.31

Value $16.6B

-1.25%
NBIX's page

Merck & Company (MRK) has a market value of $357B and Neurocrine Biosciences (NBIX) $16.6B. Over the last year, with dividends, MRK moved +60.0% and NBIX +14.1%. The P/E is 145.6 for MRK and 23.6 for NBIX. Dividend yield: MRK 2.35%, NBIX none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    MRK$357B

    NBIX$16.6B

    MRK is 22 times NBIX

  • Revenue, 12 months

    MRK$67.4B

    NBIX$3.7B

    MRK is 18 times NBIX

  • Net income, 12 months

    MRK$2.5B

    NBIX$703M

    MRK is 3.5 times NBIX

  • Operating margin

    MRK–

    NBIX24.0%

  • ROIC

    MRK3.9%

    NBIX19.4%

    15.5 points apart

  • P/E

    MRK145.6

    NBIX23.6

    MRK is 6.2 times NBIX

  • Dividend yield

    MRK2.4%

    NBIX0.0%

    2.4 points apart

  • 5-year return

    MRK+101.1%

    NBIX+88.3%

    12.8 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

MRK+101.1%

NBIX+88.3%

10015020020222023202420252026
Returns by period
PeriodMRKWith dividendsNBIXWith dividends
1 year since November 14, 2025+60.0%Price +55.5%+14.1%Price +14.1%
3 years since November 16, 2023+55.2%+15.8% a yearPrice +41.6%+52.0%+15.0% a yearPrice +52.0%
5 years since November 15, 2021+101.1%+15.0% a yearPrice +72.6%+88.3%+13.5% a yearPrice +88.3%
10 years since November 17, 2016+227.6%+12.6% a yearPrice +141.5%+216.3%+12.2% a yearPrice +216.3%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

MRKMerck & CompanyNBIXNeurocrine Biosciences

Valuation

MRKNBIX
Valuation
Price$144.46$165.31
Market value$357B$16.6B
Enterprise value (EV)$401B$15.9B
P/E145.623.6
P/E, 5-year median14.853.3
P/B8.04.3
EV/EBIT84.317.9
Free cash flow yield4.1%6.3%

Results and growth

MRKNBIX
Results and growth
Revenue, 12 months$67.4B$3.7B
Net income, 12 months$2.5B$703M
Free cash flow, 12 months$14.7B$1.0B
Earnings per share, 12 months$0.98$6.74
Revenue growth, year on year1.3%21.5%
Revenue growth a year, past+9.4%over 5 years+22.3%over 5 years
EPS growth a year, past+21.2%over 5 years+2.3%over 5 years

Margins and returns on capital

MRKNBIX
Margins and returns on capital
Gross margin71.8%97.8%
Operating margin–24.0%
Net margin3.6%19.0%
ROIC3.9%19.4%
ROE5.2%20.4%

Balance sheet

MRKNBIX
Balance sheet
Cash$9.7B$738M
Total debt$53.8B$452M
Net debt / EBITDA5.7-0.8
Interest cover2.4×–

Dividends and buybacks

MRKNBIX
Dividends and buybacks
Dividend yield2.4%–
Dividend per share, 12 months$3.40–
Dividend growth a year, past+5.8%over 5 years–
Buyback yield1.4%1.0%
Shareholder yield3.8%1.0%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: MRK or NBIX

Didn't find what you were looking for?

Ask us
Which is bigger, Merck & Company or Neurocrine Biosciences?

By market value, Merck & Company ($357B) is about 21.5 times Neurocrine Biosciences ($16.6B), at today's prices.

How did MRK and NBIX stock do over the last 10 years?

Since November 17, 2016, MRK's price moved +141.5% and NBIX's +216.3%. With dividends: MRK +227.6% (+12.6% a year), NBIX +216.3% (+12.2% a year). Past returns do not predict future ones.

Which pays the higher dividend, MRK or NBIX?

The dividend yield at today's price is 2.35% for Merck & Company and none for Neurocrine Biosciences. Over the last twelve months they paid $3.40 and – per share.

What is the P/E of MRK and NBIX?

At today's price, the P/E is 145.6 for MRK and 23.6 for NBIX. The median of the last five years was 14.8 and 53.3, which shows where each stands against its own past.

Which has the higher profit margins, Merck & Company or Neurocrine Biosciences?

Over the last twelve months, the net margin was 3.6% for Merck & Company and 19.0% for Neurocrine Biosciences, and the operating margin – and 24.0%. Revenue was $67.4B and $3.7B.

Which is the better investment, Merck & Company or Neurocrine Biosciences?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.